Diaryl Macrocyclic Triple Kinase Inhibitor Overcomes EGFR Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR inhibitors for treating cancers with EGFR mutations face limitations due to acquired drug resistance, where secondary mutations like T790M in the ATP-binding pocket of the tyrosine kinase domain allow cancer cells to continue signaling, and intrinsic or acquired resistance mechanisms such as bypass signaling pathways and phenotypical changes hinder prolonged clinical response.
Innovation Solution
Combining an EGFR inhibitor with a triple inhibitor of FAK, SRC, and JAK2 to target cancer cells, where the compound inhibits FAK, SRC, and JAK2 in conjunction with an EGFR inhibitor, either as a synergistic composition or in fixed/free combination, to overcome resistance mechanisms and enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent EGFR-TKI therapy is used, then initial tumor response is achieved, but acquired drug resistance develops after median of approximately 12 months
Solution Approach 1:
The patent combines EGFR-TKI therapy with a triple inhibitor of FAK, SRC, and JAK2 into a fixed or free combination regimen. This merging of multiple therapeutic agents targets both the primary EGFR mutation and the resistance mechanisms simultaneously, thereby extending the duration of clinical response beyond the typical 12-month limitation of single-agent therapy.
Solution Approach 2:
The treatment approach segments the resistance problem into multiple targetable components: the primary EGFR kinase activity, the FAK-mediated signaling pathway, the SRC kinase activity, and the JAK2-mediated downstream signaling. By addressing each segment with a specific inhibitor, the patent prevents any single resistance mechanism from dominating and causing treatment failure.
2Reliability
If combination therapy with multiple agents is used, then therapeutic efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges three distinct kinase inhibitors (FAK, SRC, and JAK2) into a single triple inhibitor compound or coordinated regimen that can be administered together with EGFR-TKI. This consolidation approach enhances therapeutic efficacy by targeting multiple resistance pathways simultaneously while managing the complexity through a unified treatment protocol rather than separate administrations of multiple individual agents.
Data Source
AI summary
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.